ATE149089T1 - Anwendungsgebiete von beta-adrenergenen agonisten - Google Patents

Anwendungsgebiete von beta-adrenergenen agonisten

Info

Publication number
ATE149089T1
ATE149089T1 AT88308402T AT88308402T ATE149089T1 AT E149089 T1 ATE149089 T1 AT E149089T1 AT 88308402 T AT88308402 T AT 88308402T AT 88308402 T AT88308402 T AT 88308402T AT E149089 T1 ATE149089 T1 AT E149089T1
Authority
AT
Austria
Prior art keywords
beta
effects
adrenergic
agonists
reversing
Prior art date
Application number
AT88308402T
Other languages
English (en)
Inventor
Charlotte Anne Maltin
Peter John Reeds
Margret Inkster Delday
Susan Mary Hay
Frazer George Smith
Gerald Edward Lobley
Patricia Margret Dorward
Robert Michael Palmer
Kenneth Charles Mchardy
Original Assignee
Rowett Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878721602A external-priority patent/GB8721602D0/en
Priority claimed from GB888803619A external-priority patent/GB8803619D0/en
Application filed by Rowett Research Inst filed Critical Rowett Research Inst
Application granted granted Critical
Publication of ATE149089T1 publication Critical patent/ATE149089T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
AT88308402T 1987-09-15 1988-09-12 Anwendungsgebiete von beta-adrenergenen agonisten ATE149089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878721602A GB8721602D0 (en) 1987-09-15 1987-09-15 Therapeutic applications of beta-adrenergic agonists
GB888803619A GB8803619D0 (en) 1988-02-17 1988-02-17 Therapeutic applications of beta-adrenergic agonists

Publications (1)

Publication Number Publication Date
ATE149089T1 true ATE149089T1 (de) 1997-03-15

Family

ID=26292734

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88308402T ATE149089T1 (de) 1987-09-15 1988-09-12 Anwendungsgebiete von beta-adrenergenen agonisten

Country Status (4)

Country Link
EP (2) EP0662324A1 (de)
AT (1) ATE149089T1 (de)
DE (1) DE3855801T2 (de)
ES (1) ES2100148T3 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203040B (en) * 1988-07-05 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing weight-increasing composition containing 1-(3,5-dihydroxy-phenyl)-2-(terc-butyl-amino)-ethanol
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
EP0488435A1 (de) * 1990-11-26 1992-06-03 Duphar International Research B.V Verfahren zur Steigerung des Muskel/Fett-Verhältnisses bei landwirtschaftlichen Nutztieren
US6524532B1 (en) 1995-06-20 2003-02-25 The Regents Of The University Of California Microfabricated sleeve devices for chemical reactions
US6015837A (en) * 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US8080528B2 (en) 2005-12-22 2011-12-20 The Releef Initiative Compositions and methods for treatment of cachexia
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
WO2008129308A2 (en) 2007-04-24 2008-10-30 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60530A (en) * 1979-08-16 1984-10-31 American Cyanamid Co Animal feed compositions useful as growth promotors and for reduction of fat in animals,comprising phenylethanolamine derivatives and certain such novel compounds
EP0117647B1 (de) * 1983-01-31 1988-08-17 Eli Lilly And Company Phenethanolamine
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours

Also Published As

Publication number Publication date
ES2100148T3 (es) 1997-06-16
EP0308157A2 (de) 1989-03-22
DE3855801D1 (de) 1997-04-03
DE3855801T2 (de) 1997-07-03
EP0308157B1 (de) 1997-02-26
EP0662324A1 (de) 1995-07-12
EP0308157A3 (de) 1992-01-15

Similar Documents

Publication Publication Date Title
DE3855801D1 (de) Anwendungsgebiete von beta-adrenergenen Agonisten
DE69636278D1 (de) Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
ATA242288A (de) Dosierungsform für die behandlung kardiovaskulärer erkrankungen
BE891528A (fr) Composition huileuse destinee au traitement des matieres keratiniques et de la peau
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
EP0401903A3 (de) Verwendung von Vanilloiden zur Behandlung von Erkrankungen der Atemwege
DE69022953T2 (de) Zusammensetzungen zur Behandlung von Fettablagerungen.
IL68350A0 (en) N-glycosylated carboxamide derivatives,their preparation and their use for the treatment of animals
ZA898605B (en) Compositions for topical treatment of skin diseases
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
DE3889974T2 (de) Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
BE884756A (fr) Composition dermatologique pour le traitement des maladies de la peau, accompagnees d'une proliferation cellulaire, telles que le psoriasis
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ZA822158B (de)
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
ATE197764T1 (de) Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
ATE109349T1 (de) 3-substituierte-2-oxindolderivate als interleukin-biosynthesehemmer.
ZA884315B (en) Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
DE69118847D1 (de) Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
SU1797195A1 (ru) Способ профилактики радиационных поражений
BE885851A (fr) Composition therapeutique pour le traitement de la dustrophie musculaire, de la myopathie et de la myotonie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee